Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (Selicrelumab) in Combination With Anti-PDL1 (Atezolizumab) in Patients With Refractory or Relapsed B Cell Lymphoma

NCT03892525 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.

NCT NCT03892525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03892525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (Selicrelumab) in Combination With Anti-PDL1 (Atezolizumab) in Patients With Refractory or Relapsed B Cell Lymphoma
Lead sponsor
The Lymphoma Academic Research Organisation
Phase
Phase 1
Overall status
Terminated
Start date
July 4, 2019
Completion date
April 7, 2021
Enrollment
4 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b-cell non-hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma